[Modulation of biomarkers expression (OR, PR and C-erbB2) in breast cancer following neoadjuvant treatment].
BACKGROUND
Pre and post-operative oncological therapy in patients with breast cancer is determined, amongst other factors, by hormone receptor status and by c-erbB2 expression. The aim of this study is to determine the influence of neoadjuvant therapy on the expression of oestrogen receptor (OR), progesterone receptor (PR) and c-erbB2.


METHODS
Fifty-three patients with breast cancer diagnosed by tru-cut biopsy were studied. Patients with locally advanced carcinoma (20) had preoperative treatment. All patients underwent surgical resection. Expression of OR, PR and c-erbB2 in both the tru-cut biopsy and the gross specimen was compared.


RESULTS
We found significant differences in OR, PR expression in both biopsy and gross specimen, between the group of patients who underwent neoadjuvant treatment and the group without pre-surgical treatment. Changes in PR, OR and c-erbB2 status were found between the tru-cut biopsy and the gross specimen, in about 10 to 40% of the cases who received neoadjuvant therapy. These changes had no statistical significance.
Córdoba
A
A
Servicio de Anatomía Patológica, Hospital de Navarra, Pamplona, 31008, Spain. acordobi@cfnavarra.es
Ederra
M
M
Ariceta
I
I
Gómez
M L
ML
Arrechea
M A
MA
De Llano
P
P
Martínez-Peñuela
J M
JM
D001943:Breast Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy; D002277:Carcinoma / Q000235:genetics / Q000276:immunology / Q000628:therapy; D005260:Female; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D020360:Neoadjuvant Therapy / Q000379:methods*; D011960:Receptors, Estrogen / Q000276:immunology*; D011980:Receptors, Progesterone / Q000276:immunology*
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone